此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.

The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.

研究概览

研究类型

介入性

注册 (估计的)

660

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国、510080
        • Guangdong Provincial People's Hospital
        • 首席研究员:
          • Yilong Wu

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
  2. At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
  3. The ECOG score was 0 or 1.
  4. Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
  5. Adequate bone marrow and organ function.

Exclusion Criteria:

  1. Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
  2. Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.
  3. Participants with active, known or suspected autoimmune diseases.
  4. Other malignant tumors within 5 years before screening.
  5. Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
  6. Participants with severe cardiovascular and cerebrovascular diseases.
  7. There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
  8. Arterial and venous thrombosis events occurred within 3 months before the first administration.
  9. HIV test positive.
  10. Participants with active hepatitis B or C.

1.Evidence of active tuberculosis infection within 1 year before the first administration.

12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.

14. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:group A1-1adebrelimab + SHR-A2009

adebrelimab + SHR-A2009

adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009 (shorter-interval regimen arm)

有源比较器:group A1-2 paclitaxel or pemetrexed combined with carboplatin +adebrelimab

paclitaxel or pemetrexed combined with carboplatin +adebrelimab

实验性的:group1 A2-1adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009

adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009 (shorter-interval regimen arm)

实验性的:group2 A2-2adebrelimab + SHR-A2009 (shorter-interval regimen arm)

adebrelimab + SHR-A2009

adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009 (shorter-interval regimen arm)

有源比较器:group A2-3 adebrelimab

adebrelimab

实验性的:group1 A3-1 adebeliizumab + SHR-A2009 (longer-interval regimen arm)

adebeliizumab + SHR-A2009 (longer-interval regimen arm)

adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

实验性的:group2 A3-2 adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

adebeliizumab + SHR-A2009 (longer-interval regimen arm)

adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

有源比较器:group A3-3 adebeliizumab + platinum-containing double chemotherapy

adebeliizumab + platinum-containing double chemotherapy

实验性的:group B1-1 almonertinib combined with SHR-A2009 (longer-interval regimen arm)

almonertinib combined with SHR-A2009 (longer-interval regimen arm)

almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

实验性的:group B1-2 almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

almonertinib combined with SHR-A2009 (longer-interval regimen arm)

almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

有源比较器:group B1-3 almonertinib

almonertinib

实验性的:group B2-1 SHR-A2009 combined with almonertinib

SHR-A2009 combined with almonertinib

有源比较器:group B2-2 almonertinib monotherapy

almonertinib monotherapy

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Part A1 : pCR rate;
大体时间:about 24 months
about 24 months
Part A2 : 2-year DFS rate;
大体时间:about 24 months
about 24 months
Part A3 : pCR rate and 18-month EFS rate;
大体时间:about 18 months
about 18 months
Part B1 : 2-year DFS rate.
大体时间:about 24 months
about 24 months
Part B2 : MPR rate.
大体时间:about 24 months
about 24 months

次要结果测量

结果测量
大体时间
The incidence and grade of adverse events;
大体时间:about 48 months
about 48 months
surgical complications;
大体时间:about 24 months
about 24 months
EFS
大体时间:about 24 months ;
about 24 months ;
ORR;
大体时间:about 24 months
about 24 months
DFS and DFS rates;
大体时间:about 24 months
about 24 months
OS ;
大体时间:about 48 months
about 48 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月30日

初级完成 (估计的)

2028年12月30日

研究完成 (估计的)

2030年12月30日

研究注册日期

首次提交

2026年9月30日

首先提交符合 QC 标准的

2026年9月30日

首次发布 (实际的)

2026年10月7日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅